We have previously reported that a set of oral squamous cell carcinoma lines express speci®cally elevated cdk6 activity. One of the cell lines, SCC4, contains a cdk6 ampli®cation and expresses functional p16 ink4a , the other cell lines express undetectable levels of p16 ink4a , despite a lack of coding-region mutations. Two of the cell lines, SCC15 and SCC40 have a hypermethylated p16 ink4A promoter and a third cell line, SCC9, has a mutation in the p16 ink4a promoter. Using the demethylation agent 5-aza-2'-deoxycytidine, we showed that the p16 ink4a protein was re-expressed after a 5-day treatment with this chemical. One cell line, SCC15 expressed high levels of p16 ink4a . In this line, cdk6 activity was decreased after 5-aza-2'deoxycytidine treatment, and the hypophosphorylated, growth suppressive form of the retinoblastoma tumor suppressor protein pRB was detected. Expression of p16 ink4a persisted, even after the drug was removed and the cells expressed senescence-associated b-galactosidase activity. Ectopic expression of p16 ink4a with a recombinant retrovirus in this cell line also induced a similar senescence-like phenotype. Hence, it was possible to restore a functional pRB pathway in an oral squamous cell carcinoma line by inducing re-expression of endogenous p16 ink4a in response to treatment with a demethylating agent.
Introduction
Head and neck cancers are the sixth most common malignancy worldwide (Parkin et al., 1988) . Generally, these carcinomas are accessible for early diagnosis, but they are associated with a high rate of mortality (Fernandez-Martinez et al., 1995) , indicating the need for improved cancer therapy and a better understanding of the molecular changes underlying cancer development.
Tumor formation is generally accompanied by a marked upregulation of proliferation. The retinoblastoma tumor suppressor gene product (pRB) is an important checkpoint for proliferation control at the G1/S boundary (reviewed in Bartek et al., 1996) . The growth-suppressive activity of pRB is modulated by cell cycle-dependent phosphorylation and dephosphorylation events (reviewed in Weinberg, 1995) . Complexes of cyclin D with cdk4 or cdk6 play important roles in pRB phosphorylation at the G1/S transition of the cell division cycle (Kato et al., 1993; Matsushime et al., 1994; Meyerson and Harlow, 1994) . The relative levels of cyclin D and/or cdk4 and cdk6 are signi®cant determinants for the enzymatic activities of these complexes (reviewed in Sherr, 1994) . In addition, the ink4 family of kinase inhibitors also critically contributes to the regulation of cdk4 and cdk6-associated kinase activity (Serrano et al., 1993; Hannon and Beach, 1994) . Moreover, upregulation of p16 ink4a a member of the ink4 family, has been observed during the late stages of senescence, where proliferation ceases terminally (Alcorta et al., 1996) . Consistent with a role in regulating senescence, p16 ink4a expression was lost in mammary epithelial cells that escaped from the M0 proliferation block (Foster et al., 1998) and ectopic expression of p16 ink4a induced termination of proliferation and a senescence-like state in human glioma cells (Uhrbom et al., 1997) .
The pRB tumor suppressor pathway is dysregulated in the majority of all cancers. Dierent cancers show aberrations in a distinct subset of proteins in this regulatory circuit (reviewed in Hall and Peters, 1996) . For example, p16 ink4a mutations are common in melanomas (Pollock et al., 1996) , whereas retinoblastomas, many sarcomas and small cell lung carcinomas contain deletions or mutations in the RB gene (Horowitz et al., 1990) . Aberrant cyclin D1 levels are frequently observed in breast cancers (Buckley et al., 1993) , while cdk4 ampli®cation and overexpression has been noted in some brain cancers (He et al., 1995; Sonoda et al., 1995) . Deregulation of cdk6 activity has been detected in a panel of oral squamous cell carcinoma (SCC) lines (Timmermann et al., 1997) and two cases of cdk6 overexpression have been reported in gliomas (Costello et al., 1997) .
One of the oral SCC lines described above contained an ampli®cation of the cdk6 gene and overexpressed the cdk6 protein, establishing a likely cause for the observed elevation of cdk6 activity. In the other SCC lines, we detected very little, if any, p16 ink4a expression, and we hypothesized that absence of p16 ink4a expression may account for the speci®c elevation of cdk6 kinase activity. However, evaluation of the p16 ink4a coding region did not reveal any mutations (Timmermann et al., 1997) .
Deletions and mutations of the p16 ink4a gene have been described in several oral cancers and cell lines (Zhang et al., 1994; Lydiatt et al., 1995; Reed et al., 1996) , and recently, loss of p16 ink4a protein expression in oral carcinomas has also been linked to promoter hypermethylation (Loughran et al., 1996) . One speci®c CpG island in the p16 ink4a gene was found methylated in 20% of primary head and neck cancers (Gonzalez et al., 1997) . Demethylating agents, such as 5-aza-2'-deoxycytidine (5-Aza-CdR) can decrease methylation levels, and have been shown to re-establish p16 ink4a expression (Otterson et al., 1995) . Therefore, we investigated whether lack of p16 ink4a expression in the oral SCC cell lines may be caused by methylation of the p16 ink4a promoter, if demethylation by treatment with 5-Aza-CdR could lead to re-expression of p16 ink4a and whether re-expression of endogenous p16 ink4a could restore growth suppression by the pRB pathway.
We detected hypermethylation of the p16 ink4a promoter in two cell lines, SCC15 and SCC40, while a third line showed evidence of a mutation in this area of the promoter. Treatment with 5-Aza-CdR resulted in demethylation of the promoter and re-expression of the protein in SCC15 and SCC40. Furthermore, the p16 ink4a expressed in response to this treatment is a functional protein in that it binds to and inhibits cdk6 and cdk4 kinases. Higher levels of expression detected in SCC15 result in hypophosphorylation of the pRB protein. Consistent with a role of p16 ink4a in regulating cellular senescence we demonstrate that 5-Aza-CdRmediated re-expression of endogenous p16 ink4a , as well as ectopic expression of p16 ink4a by retroviral gene transfer, induces a senescence-like state as shown by increased activity of a b-galactosidase marker and changes in morphology.
Results

The p16
ink4a gene is silenced by methylation in two oral SCC lines
We previously showed that the pRB pathway is disrupted by speci®c upregulation of cdk6 kinase activity in each of the ®ve oral squamous cell carcinoma lines SCC4, SCC9, SCC13, SCC15 and SCC40. Elevated cdk6 protein levels were detected in SCC4 and likely are responsible for the observed elevated cdk6 kinase activity (Timmermann et al., 1997) . Using a combination of immunoprecipitation and immunoblotting, no p16 ink4a protein was detected in SCC9, 13, 15 and 40 ( Figure 1a) . However, previous analyses of the p16 ink4a gene in these lines had not revealed any mutations in the coding sequence of p16 ink4a (Zhang et al., 1994; Timmermann et al., 1997) .
Because p16 ink4a protein expression is frequently abrogated by de novo methylation of the p16 ink4a promoter, we decided to determine the methylation status of the p16 ink4a promoter in the ®ve oral carcinoma lines (Figure 1b) . A non-quantitative PCR procedure was employed that allows for detection of methylated and non-methylated DNA sequences (Herman et al., 1996) . Only unmethylated DNA was detected in the cell line SCC4 at this site of the p16 ink4a promoter ( Figure  1b ). This was expected since the p16 ink4a protein is expressed in the SCC4 line ( Figure 1a) . Analysis of SCC15 and SCC40 revealed exclusively methylated sequences at this site of the p16 ink4a promoter, indicating that loss of p16 ink4a protein in these cell lines may be due to promoter methylation (Figure 1a,b) . In SCC9, no PCR product was detected with either primer pair in three independent experiments. The integrity of the genomic template DNA was con®rmed with a control PCR that successfully ampli®ed the second exon of p16 ink4a (Figure 1b lower panel) . PCR analysis of unmodi®ed DNA similarly did not lead to amplification of a PCR product (data not shown). These results suggest that this cell line may have a mutation at this site of the p16 ink4a promoter region. Analysis of the SCC13 cell line showed that it contained exclusively unmethylated product. We concluded that methylation is a candidate mechanism for silencing p16 ink4a protein expression in SCC15 and 40.
5-Aza-CdR promotes demethylation of the p16 ink4a gene
The chemical 5-Aza-CdR, a cytidine analog, eectively leads to demethylation of DNA (Creusot et al., 1982; Michalowsky and Jones, 1987) and may restore transcription from promoters that were inactivated by hypermethylation.
When treated with 5-Aza-CdR, demethylation of the p16 ink4a promoter was observed in SCC15 and 40 cells as assessed by methylation-sensitive PCR (Figure 2 ). Whereas unmethylated p16 ink4a promoter was consistently detected in SCC15 after 35 cycles of PCR ampli®cation, 60 cycles of ampli®cation were necessary to visualize a PCR fragment in SCC40. As higher concentrations of 5-Aza-CdR led to pronounced cellular toxicity in several SCC lines, it was not tested whether higher concentrations of 5-Aza-CdR would lead to a more ecient demethylation in SCC40 cells. ink4a promoter. Genomic DNA was bisul®te treated, converting unmethylated cytosine residues into uracil residues. The DNA was then subjected to methylation-speci®c ampli®cation of the p16 ink4a promoter. Two dierent sets of primers were used to speci®cally amplify methylated and unmethylated target DNA. M denotes the marker lane. See Materials and methods for details. In the lower panel, the integrity of the genomic DNA was ascertained for all cell lines by ampli®cation of the second exon of p16 ink4a protein levels increased in SCC40 (Figure 4a ). To assure that the newly synthesized p16 ink4a was able to bind to cdks, we determined complex formation in SCC15 and SCC40 by immunoprecipitation/immunoblot analysis. After treatment with 5-Aza-CdR, cdk6/p16 ink4a complexes were detected in SCC15 and to a much lesser extent also in SCC40, the two cell lines re-expressing p16 ink4a ( Figure 3a) . Similarly, cdk4/p16 ink4a complexes were also detected in these lines (data not shown).
Complexes of p16
ink4a with cdk6 or cdk4 were absent in untreated SCC9, 13, 15 and 40 cells ( Figure 3a and data not shown), demonstrating that these complexes were formed in response to promoter demethylation.
5-Aza-CdR treatment globally changes the methylation of the genome (Creusot et al., 1982; Michalowsky and Jones, 1987) and, therefore, it is likely that in addition to p16 ink4a it will also aect expression of many other genes. We investigated the steady state levels of selected proteins involved in G1/S transition to ensure that any changes in cdk6 complex composition and cdk6 kinase activity were not due to dierential expression of other known regulators of the cdk6 complex. Protein levels of cdk6 and the regulatory subunit cyclin D1 did not change with 5-Aza-CdR treatment ( Figure 3a) . Similarly, levels of cdk4 and cyclin-dependent kinase inhibitors p21 cip1 , p27 kip1 and p18 ink4c remained unchanged in SCC9, 13, 15 or 40 (data not shown).
Since p16 ink4a /cdk6 complexes were detected after 5-Aza-CdR treatment in SCC15 and to a lesser extent also in SCC40 cells, we wanted to determine whether, as a consequence, cdk6-associated pRB-kinase activity was decreased in the SCC15 and SCC40 lines ( Figure  3b , upper panel). In two independent experiments, cdk6 kinase activity was inhibited between 43 ± 60% in SCC15 and between 21 ± 46% in SCC40 after treatment. In contrast, there was very little, if any, inhibition of cdk6 activity in the other SCC lines where there was no induction of p16 ink4a in response to 5-AzaCdR treatment. Similarly, cdk4 kinase activity was also reduced in SCC15 and 40 cells, but not in the other cell lines (data not shown). These results suggest that p16 ink4a , when reexpressed after demethylation of the promoter in SCC15 and SCC40, is a functional protein. The absence of cdk inhibition in those SCC lines where there is no p16 ink4a expression in response to the demethylation agent also strongly suggests that inhibition of the kinase activity is a speci®c result of reexpression of p16 ink4a and not due to treatment with 5-Aza-CdR per se.
As pRB is a physiologically relevant substrate for the cdk6 and cdk4 kinases, we investigated the phosphorylation status of pRB in response to 5-AzaCdR treatment (Figure 3c ). Mock treated SCC15 cells contained both hyper-and hypophosphorylated forms of pRB; however, after 5-Aza-CdR treatment there was an increase in hypophosphorylated pRB in this cell line, suggesting that the observed inhibition of cdk6 by de novo p16 ink4a expression may be sucient to lead to a decreased phosphorylation of pRB. Results similar to those shown in the ®gure were obtained in two additional independent experiments.
In SCC40, cdk4 and cdk6 kinase activities are also diminished during 5-Aza-CdR treatment, but there was no marked alteration in the state of pRB phosphorylation in response to this treatment. This may be due to the lower levels of p16 ink4a that are expressed in SCC40 cells after 5-Aza-CdR treatment (Figure 3a) . In SCC4, 9, and 13 where there is no p16 ink4a induction or inhibition of cdk6 activity, the phosphorylation status of pRB did not change. In all cells, 5-Aza-CdR ink4a promoter in SCC15 and SCC40. Cells were treated with or without 3 mM 5-Aza-CdR for 5 days. Methylation-sensitive PCR was performed as described in Materials and methods. Reverse images of the ethidium bromide stained gels are displayed and the number of rounds of ampli®cation is noted. Since these are nonquantitative assays, the relative intensities of the bands do not re¯ect absolute changes in relative abundances treatment led to a general decrease in pRB levels, but the mechanism of this is unknown to us.
These results show that it has been possible to restore the pRB pathway in SCC15 cells by inducing re-expression of endogenous p16 ink4a . This is consistent with our model that loss of p16 ink4a protein expression contributes to elevated cdk6 kinase activity in the oral SCC lines (Timmermann et al., 1997) .
5-Aza-CdR treatment induces a senescence-like state in cells re-expressing p16 ink4a
The p16 ink4a protein has been linked to senescence (Alcorta et al., 1996; Loughran et al., 1996; Serrano et al., 1997; Foster et al., 1998) , and as high levels of p16 ink4a were re-expressed in SCC15 after 5-Aza-CdR treatment, we investigated whether re-expression of p16 ink4a in this cancer cell line would prompt the cells to undergo senescence.
Re-expression of p16 ink4a is maintained in SCC15 and SCC40 lines even after the drug is withdrawn. We detected p16 ink4a protein in SCC15 after 5 days of 5-Aza-CdR treatment and a ten-day post-treatment recovery phase (Figure 4a ). Similar results were obtained for SCC40. Cells undergoing senescence express a number of senescence-speci®c genes including a b-galactosidase activity with a characteristic pH optimum at pH 6.0 (Dimri et al., 1995) . Activity of this senescence-associated b-galactosidase was therefore analysed at 8 ± 10 days after drug withdrawal. Cells that were strongly positive for b-galactosidase staining were detected in SCC15, but not in mock treated SCC15 cells or in control SCC4 cells (Figure 4b ). Compared to mock treated SCC15 cells, cells treated with 5-Aza-CdR showed a 30-fold increase in the number of b-galactosidase positive cells. The absolute number of stained cells and the fold increase over untreated cells were much lower in SCC4, 9 and 40 (Figure 4c) . Activation of the senescence-associated bgalactosidase, therefore, coincides with strong p16 ink4a expression and the restoration of the pRB pathway.
Infection with a recombinant retrovirus encoding p16 ink4a induces a senescence-like state After having shown that induction of senescence in response to 5-Aza-CdR treatment correlated with p16 ink4a induction in the SCC lines, we wanted to ensure that p16 ink4a expression was sucient to induce this phenotype in these cells. Therefore, we tested whether ectopic p16 ink4a expression in the oral SCC lines could induce senescence-like changes similar to those observed after 5-Aza-CdR treatment. We introduced p16 ink4a into SCC15 cells by retroviral infection and evaluated the induction of senescence associated bgalactosidase activity. SCC15 cells were infected with either a control retrovirus, or recombinant retroviruses expressing either wild type p16 ink4a or an inactive p16 ink4a protein with an arginine 87 to proline substitution that is unable to bind to cdk4 (Koh et al., 1995) . Similar amounts of both wild type and mutant p16 ink4a proteins were detected by immunoprecipitation/immunoblot analysis after infection (Figure 5a ). The dierences in electrophoretic mobility are due to the fact that the wild type p16 ink4a gene, but not the mutant version, is missing eight amino acids at the amino terminus. Infection of SCC15 with wild type p16 ink4a , but not with mutant p16 ink4a or control vector, induced senescenceassociated b-galactosidase activity (Figure 5b ). We detected a 40-fold increase of b-galactosidase activity in cells harboring wild type p16 ink4a in comparison to cells infected with the p16 ink4a mutant or the control vector (Figure 5c ). In addition, there was a dramatic increase in cell size in the p16 ink4a expressing SCC15 cells. Similar experiments with SCC4 cells also resulted in an increase of senescence-associated b-galactosidase activity (data not shown). These results further support the notion that the induction of a senescence-like state in SCC15 after treatment with 5-Aza-CdR (Figure 4) is a consequence of re-expression of p16 ink4a .
Discussion
We have previously reported that cdk6 is speci®cally hyperactive in a panel of oral SCC lines. While one line (SCC4) showed overexpression of cdk6, the remaining SCC lines showed decreased expression of p16 ink4a (Timmermann et al., 1997) . Here we have analysed the status of p16 ink4a in more detail and have shown that there are several mechanisms that contribute to this defect. None of the cell lines showed evidence for mutation in the coding sequence of p16 ink4a (Zhang et al., 1994; Timmermann et al., 1997) . However, analysis of a portion of the promoter containing a CpG island that is often hypermethylated using a procedure that allows for speci®c detection of methylated and unmethylated sequences (Herman et al., 1996) revealed that three of the four cell lines had aberrations. In one cell line, SCC9, we failed to generate a PCR product with either primer pair (Figure 1b) , suggesting that there was a mutation in this critical promoter region of the p16 ink4a gene. The p16 ink4a promoter of the SCC9 cell line is therefore currently under investigation in our laboratory. In two other cell lines, SCC15 and SCC40, we detected only methylated promoter sequences, consistent with inhibition of p16 ink4a expression by this mechanism. A fourth cell line, SCC13, only showed unmethylated DNA, but failed to express p16 ink4a protein. While the p16 ink4a promoter in SCC13 might potentially be methylated at a site dierent from the one that was assayed (Gonzalgo et al., 1998), this possibility seems less likely as treatment with the demethylating agent 5-Aza-CdR did not restore protein expression (Figure 3a) . Still, we can not exclude the possibility that the levels of 5-Aza-CdR used in these experiments are not sucient to lead to demethylation at an alternative site in SCC13.
Expression of a variety of tumor suppressor genes, such as VHL (Herman et al., 1994) and p16 ink4a (Merlo et al., 1995; Otterson et al., 1995) , have been shown to be extinguished in tumors by hypermethylation. While re-expression of the p16 ink4a protein by treatment with 5-Aza-CdR has been described before, it has only recently been shown that such re-expression is linked to G1 arrest and a lengthening of population doubling times . Here we show for the ®rst time that the biological and biochemical consequences of this re-expression are mediated through a restoration of the pRB pathway and induction of senescence. Our results show that treatment with the demethylating chemical 5-Aza-CdR caused re-expression of the cdk4/ 6 inhibitor p16 ink4a in the oral squamous carcinoma cell lines SCC15 and SCC40. The SCC15 cell line was more responsive to treatment with this chemical and the levels of re-expressed p16 ink4a in this cell line were consistently higher than in SCC40. The inhibitory activity of the p16 ink4a protein was demonstrated by its ability to bind cdk4 and cdk6 kinases and inhibit their activities (Figure 3 and data not shown). Ultimately, treatment induced a senescence-like state in SCC15. Because p16 ink4a expression from a retrovirus is sucient to induce this senescence-like state in SCC15 (Figure 5 ), we conclude that the reactivation of the endogenous p16 ink4a gene by 5-Aza-CdRmediated demethylation critically contributes to the senescence-related changes in SCC15. This indicates that while methylation of a gene is functionally similar to an inactivating mutation, demethylation of this gene can successfully restore its function.
Lack of p16 ink4a expression in SCC15 and 40 correlated with methylation of the p16 ink4a promoter. While treatment with 5-Aza-CdR led to re-expression of p16 ink4a protein in these cell lines, it did not lead to full demethylation of the p16 ink4a promoter. Comparable levels of demethylation eciency were observed in lung cancer cell lines that were similarly treated with 5-Aza-CdR (Otterson et al., 1995) . 5-Aza-CdR also induced p16 ink4a protein expression in these lines. Complete demethylation of the p16 ink4a promoter is, therefore, not required for p16 ink4a protein expression. Both SCC15 and SCC40 contained exclusively methylated p16 ink4a promoters, but the amounts of p16 ink4a detectable after a 5-day treatment with 5-AzaCdR in these two cell lines was strikingly dierent (Figure 3) . As 5-Aza-CdR forms covalent, inactivating intermediates with the methyl transferases (JuÈ ttermann et al., 1994) , high levels of methyl transferases may not be completely inactivated at the 5-Aza-CdR doses used in these experiments. Higher levels of methyl transferase in SCC40 than SCC15 may, therefore, explain the disparate levels of demethylation. The dierences in demethylation eciency of SCC15 and SCC40 translated into noticeable dierences in the amount of re-expressed p16 ink4a protein. After a 5-day treatment, SCC40 cells expressed barely detectable levels of p16 ink4a (Figure 3) , there was less inhibition of cdk6 activity and consequently no accumulation of hypophosphorylated pRB was observed. Furthermore, the detection of hypophosphorylated forms of the pRB protein in all cell lines indicates that other inhibitors also contribute to regulation of pRB phosphorylation. As Koh and coworkers demonstrated that the inhibitory activity of p16 ink4a is dose dependent (Koh et al., 1995) , it is conceivable that the amount of p16 ink4a expressed in SCC40 after 5-Aza-CdR treatment is below the threshold necessary for cdk6 inhibition to result in accumulation of hypophosphorylated pRB. The p16 ink4a protein levels in SCC40 cells after a 10-day recovery phase were considerably higher when compared to the levels after 5 days of 5-Aza-CdR treatment. Nevertheless, senescence induction was still low in SCC40 cells at this later timepoint. Therefore, the induction of p16 ink4a may have occurred too late to lead to detectable hallmarks of senescence at this timepoint.
Inappropriate cell division is a characteristic of most tumors (reviewed in Sherr, 1996) . Senescent cells, on the other hand, have permanently ceased cell proliferation, even though they remain metabolically active for long periods of time. Altered gene expression and physiology have been observed in senescent cells (reviewed in Stein and Dulic, 1995) , but the mechanisms behind these changes are poorly understood. In the absence of better mechanistic markers of cellular senescence, induction of b-galactosidase with a pH optimum at pH 6.0 has been used to assay cellular senescence (Dimri et al., 1995) . Accumulation of the p16 ink4a protein has been associated with the onset of senescence in a number of studies. For example, p16 ink4a expression increases dramatically at late stages of replicative senescence in human diploid ®broblasts (Alcorta et al., 1996) . In mammary epithelial cells inactivation of p16 ink4a by CpG island methylation was shown to be associated with escape from the M0 proliferation block (Foster et al., 1998) . Moreover, engineered expression of p16 ink4a in a human glioma cell line with a p16 ink4a deletion led to the onset of senescence, as determined by induction of senescencespeci®c b-galactosidase activity and was accompanied by changes in cellular morphology (Uhrbom et al., 1997) . We observed very similar eects, including a dramatic increase in cell size in SCC15 cells both in response to re-expression of endogenous p16 ink4a and when p16 ink4a expression was enforced by a retrovirus. The results presented here are consistent with the concept that p16 ink4a plays an important role during senescence in vivo. Moreover, our results suggest that it may be possible to achieve senescence of tumors where p16 ink4a expression is extinguished as a cause of promoter methylation, through re-expression of p16 ink4a by promoter demethylation. Recently, upregulation of the p53 protein has also been associated with senescence (Serrano et al., 1997) . The p53 pathway in the SCC lines investigated here has previously been analysed and all of the lines showed evidence for non-functional p53 (Burns et al., 1993; Min et al., 1994; S Timmermann and K MuÈ nger, unpublished) . 5-Aza-CdR treatment restored the pRB pathway in SCC cells by re-expressing p16 ink4a protein. Consistent with the inactivation of p53, the treatment, however, did not induce changes in p53 or p21 cip1 protein levels in SCC15 or SCC40 (data not shown). These results show that functional p53 protein is dispensable for induction of senescence by p16 ink4a .
Senescence by re-expression of endogenous p16 ink4a S Timmermann et al Serrano and coworkers similarly found that induction of senescence in human ®broblasts by ras required either functional p53 or p16 ink4a protein, but not necessarily both (Serrano et al., 1997) .
The induction of a senescence-like state in an oral SCC line in response to 5-Aza-CdR highlights its potential role as a chemotherapeutic drug. Methylation of the p16 ink4a promoter has been detected in many dierent tumor types (Baylin et al., 1997; Liggett and Sidransky 1998) . Clinical trials with 5-Aza-CdR have been performed with head and neck SCCs (Abele et al., 1987) as well as acute myeloid leukemias (Schwartsmann et al., 1997; Willemze et al., 1997) , with varying results in terms of patient remission and survival. However, no information about genetic changes in the treated tumors was available in these trials. A controlled study with 5-Aza-CdR or other demethylating agents using cancers grouped according to the methylation status of the p16 ink4a gene may prove more insightful. Moreover, it will be important to analyse the ecacy of such drugs to induce robust levels of p16 ink4a expression in the tumors after drug treatment.
Materials and methods
Cell lines and cell culture
The following squamous cell carcinoma lines were analysed: SCC4, SCC9, SCC13, SCC15 and SCC40. SCC4, SCC9 and SCC15 were obtained from ATCC, and SCC13 and SCC40 were kind gifts from Dr James Rheinwald (Brigham and Women's Hospital, Boston, MA, USA). SCC4 was derived from a carcinoma of the tongue that was exposed to radiation and methotrexate prior to establishment as a cell line (Rheinwald and Beckett, 1980, 1981) . SCC9 and SCC15 were derived from carcinomas of the tongue without prior treatment (Rheinwald and Beckett, 1980, 1981) . SCC13 was established from an epidermal tumor after radiation treatment and SCC40 from a soft palate cancer. All SCC lines were grown in Ham's F12: DMEM (1 : 1) supplemented with 10% fetal bovine serum, 24 mg/ml adenine, 0.4 mg/ ml hydrocortisone and 50 units/ml penicillin and streptomycin. This medium was mixed 1 : 1 with sterile-®ltered conditioned medium derived from J2 NIH3T3 cells (ATCC) cultured for 48 h in DMEM with 10% fetal bovine serum (SCC/J2 media). 293GPG cells (a kind gift of Dr Richard Mulligan, Massachusetts Institute of Technology, Cambridge, MA, USA) (Ory et al., 1996) were grown in 293-growth media (DMEM supplemented with 10% FBS, 300 mg/ml G418, 2 mg/ml puromycin, 1 mg/ml tetracycline and 50 units/ml penicillin and streptomycin) as described (Ory et al., 1996) . After transfection, cells were grown in 293-HEPES media (DMEM supplemented with 10% FBS, 50 units/ml penicillin and streptomycin and 10 mM HEPES, pH 8.0). All experiments described in this communication were performed with asynchronous, logarithmic cultures.
5-Aza-CdR treatment
Cells were plated at 25 ± 30% con¯uence and treated 24 h later (day 0) with 0.006% DMSO (®nal concentration, control) or 3 mM 5-Aza-CdR in 0.006% DMSO. 5-AzaCdR treatment lasted for 5 days. Media containing DMSO or DMSO+5-Aza-CdR was exchanged at day 2. At day 5, cells were either harvested or washed twice in PBS and fed with normal media not containing DMSO or 5-Aza-CdR. Media was then exchanged every second day and cells harvested at day 15 (day 10 after treatment with 5-AzaCdR).
Detection of p16 ink4a promoter methylation
Genomic DNA was prepared according to standard procedures (Ausubel et al., 1992) . Primers and PCR conditions for ampli®cation of the second exon of the p16 ink4a gene were as described in Kamb et al., (1994) . Methylation-speci®c ampli®cation was performed according to Herman et al. (1996) . In brief, genomic DNA was subjected to a deamination reaction by incubation with sodium bisul®te, hydroquinone and sodium hydroxide. This converts unmethylated, but not methylated cytosine into uracil. After removal of the free bisul®te, the products were desulfonated with sodium hydroxide. The DNA was puri®ed by ethanol precipitation. For ampli®cation, primers speci®c for modi®ed methylated DNA (sense: TTA TTA GAG GGT GGG GCG GAT CGC; antisense: GAC CCC GAA CCG CGA CCG TAA) or primers speci®c for modi®ed unmethylated DNA (sense: TTA TTA GAG GGT GGG GTG GAT TGT; antisense: CAA CCC CAA ACC ACA ACC ATA A) were added to a PCR mix containing the deaminated DNA.
Immunological methods
Cells were lysed in EBC buer (50 mM Tris-HCl, 120 mM NaCl, 1% (v/v) Nonidet P40, pH 8.0) (DeCaprio et al., 1988) and the lysates cleared by centrifugation at 15 000 g for 15 min at 48C. The protein content of the cleared lysates was estimated by the method of Bradford (BioRad). The lysates were incubated with the appropriate antibody for 2 ± 12 h at 48C. Antigen-antibody complexes were immobilized on protein A sepharose (Pharmacia) and analysed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS ± PAGE). For immunoblot analysis, the samples were electro-transferred to polyvinylidenē uoride membranes (Immobilon P, Millipore) and antigen-antibody complexes were detected by enhanced chemiluminescence (Renaissance, NEN Dupont). In some cases the membranes were stripped and reprobed according to the manufacturer's protocol.
Antibodies
The antibodies were purchased from, and used according to the protocols supplied by, the following commercial suppliers: cdk6 (Santa Cruz, SC177), cyclin D1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA, SC246; PharMingen, San Diego, CA, USA, 14726E), p16 ink4a (PharMingen, 15126E and 13381A) and pRB (PharMingen, 14001A). Rabbit anti-mouse IgG was from Sigma (St. Louis, MO, USA) and horseradish-peroxidase-linked sheep anti-mouse and donkey anti-rabbit secondary antibodies were purchased from Amersham (Arlington Heights, IL, USA).
Kinase assays
Kinase assays speci®c for cdk6 were performed as described by Matsushime et al., (1994) with some modi®cations. In short, the cells were lysed with agitation for 20 min at 48C in DIP buer (50 mM HEPES-KOH, 150 mM NaCl, 1 mM EDTA, 2.5 mM EGTA, 10% (v/v) glycerol, 0.1% (v/v) Tween-20, 1 mM DTT, 2 mM NaF, 0.5 mM sodium orthovanadate, 0.5 mM PMSF, 1 mg/ml aprotinin, 1 mg/ml leupeptide, pH 7.2). Extracts were centrifuged at 15 000 g for 15 min at 48C to remove insoluble material and processed immediately. After immunoprecipitation with the appropriate antibody for 90 min at 48C and binding to protein A Sepharose (Pharmacia) for 90 min at 48C, immunocomplexes were washed four times in DIP buer and twice in kinase buer (50 mM HEPES-KOH, pH 7.2, 10 mM MgCl 2 , 5 mM MnCl 2 , 1 mM DTT, 20 mM ATP, 10 mCi/assay [g-32 P]ATP). A carboxyl terminal fragment of pRB fused to glutathione-S-transferase (a gift from Dr Ed Harlow, MGH Cancer Center, Charlestown, MA, USA) (Meyerson and Harlow, 1994) was used as a substrate. Kinase assays were performed at 378C for 30 min and analysed by SDS ± PAGE and subsequent autoradiography at room temperature. Gels were analysed with a phosphoimager (GS250 Molecular Imager, Biorad) for quantitation with the Molecular Analyst program.
Staining for b-galactosidase activity
Detection of the activity of the senescence-associated bgalactosidase (pH 6.0) followed the protocol of Dimri et al. (1995) . In brief, cells were washed in PBS, ®xed in 0.5% formaldehyde for 10 min, washed and incubated for 16 ± 24 h in freshly prepared senescence-associated b-galactosidase stain, 0.1% 5-bromo-4-chloro-3-indolyl-b-D-galactoside (X-gal); 40 mM citric acid/sodium phosphate, pH 6.0; 5 mM potassium ferrocyanide; 5 mM potassium ferricyanide; 150 mM NaCl; 2 mM MgCl 2 . For quantitation, total and stained (blue) cells were counted, between 500 ± 1000 total cells per sample.
Retroviral infections
Wild type human p16 ink4a cDNA (missing the ®rst 24 nucleotides; a gift of Robert Weinberg, Whitehead Institute, Massachusetts Institute of Technology, Cambridge, MA, USA) (Medema et al., 1995) and the kinase binding-de®cient mutant p16R87P (arginine 87 to proline substitution; a kind gift of Jim Koh, Massachusetts General Hospital, Boston, MA, USA) (Koh et al., 1995) were cloned into the BamH1 site of the LXSN vector (a kind gift of A Dusty Miller, Fred Hutchinson Cancer Center, Seattle, Washington, USA) (Miller and Rosman, 1989) . The human 293-derived retroviral packaging line 293GPG cells was used for virus production by transient transfection according to the method of Ory et al. (1996) with some modi®cations. In brief, 50% con¯uent 293GPG cells were incubated with 4 ml Optimem (Gibco/BRL) for 30 min. Sixteen mg DNA was mixed with 1.2 ml Optimem and 100 ml Lipofectamine (Gibco/BRL) and incubated for 30 min. 4.8 ml Optimem was added to the mix. This resulting DNA solution was then exchanged for the Optimem on the 293GPG cells. An additional 4 ml Optimem was added 8 h post transfection and media replaced with 293-HEPES media 24 h post transfection. Viral supernatant was collected 48, 72, 96 and 120 h post transfection. Storage of viral supernatant was at 48C until 120 h post transfection, at which point 40% con¯uent SCC cells (60 mm plates) were incubated for 48 h with a mixture of 2 ml viral supernatant, 20 mg polybrene and 0.5 ml SCC/J2 media. For protein analysis, cells were harvested after 48 h. For evaluation of senescence-associated bgalactosidase activity, cells were fed at 2-day intervals with SCC/J2 media and analysed on day 8 post-infection.
Unless otherwise noted, all experiments were performed independently at least three times.
